Normal view MARC view ISBD view

Gas sterilization of cartilage and bone implants. [electronic resource]

By:

SNYDER, C C

Contributor(s):

Producer: 19981101Description: 568-76 p. digitalISSN:

0096-8501

Subject(s):

Online resources:

Available from publisher's website

In: Plastic and reconstructive surgery and the transplantation bulletin vol. 28

Tags from this library: No tags from this library for this title. Log in to add tags.

Average rating: 0.0 (0 votes)

No physical items for this record

Publication Type: Journal Article

There are no comments on this title.

to post a comment.

Back to results

2461 Various peroxisome proliferator-activated receptor (PPAR)-γ agonists differently induce differentiation of cultured human keratinocytes.
by Yan, Yan
2462 Effects of pioglitazone and vildagliptin on coagulation cascade in diabetes mellitus--targeting thrombogenesis.
by Khan, Sana
2463 What are the preferred strategies for control of glycaemic variability in patients with type 2 diabetes mellitus?
by Zenari, L
2464 Pioglitazone-induced improvements in insulin sensitivity occur without concomitant changes in muscle mitochondrial function.
by Bajpeyi, Sudip
2465 Fixed-dose combination of alogliptin/pioglitazone improves glycemic control in Japanese patients with type 2 diabetes mellitus independent of body mass index.
by Aoki, Chie
2466 Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.
by Cusi, Kenneth
2467 Ameliorative potential of pioglitazone and ceftriaxone alone and in combination in rat model of neuropathic pain: Targeting PPARγ and GLT-1 pathways.
by Pottabathini, Raghavender
2468 Effect of Low (7.5 mg/day), Standard (15 mg/ day) and High (30 mg/day) Dose Pioglitazone Therapy on Glycemic Control and Weight Gain in Recently-Diagnosed Type 2 Diabetes Patients.
by Panikar, Vijay
2469 A selective peroxisome proliferator-activated receptor-γ agonist benefited propionic acid induced autism-like behavioral phenotypes in rats by attenuation of neuroinflammation and oxidative stress.
by Mirza, Roohi
2470 Pioglitazone attenuates kidney fibrosis via miR-21-5p modulation.
by Sun, Li
2471 Retinoprotection by BGP-15, a Hydroximic Acid Derivative, in a Type II Diabetic Rat Model Compared to Glibenclamide, Metformin, and Pioglitazone.
by Wachal, Zita
2472 The risk of sudden cardiac arrest and ventricular arrhythmia with rosiglitazone versus pioglitazone: real-world evidence on thiazolidinedione safety.
by Leonard, Charles E
2473 Altered gene expression for tumor necrosis factor-alpha and its receptors during drug and dietary modulation of insulin resistance.
by Hofmann, C
2474 Lipid response to pioglitazone in diabetic patients: clinical observations from a retrospective chart review.
by King, Allen B
2475 A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus.
by Herz, Matthias
2476 Pioglitazone: an antidiabetic drug with the potency to reduce cardiovascular mortality.
by Pfützner, Andreas
2477 Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes.
by Betteridge, D J
2478 Overexpression of GLUT5 in diabetic muscle is reversed by pioglitazone.
by Stuart, Charles A
2479 Pioglitazone attenuates the severity of sodium taurocholate-induced severe acute pancreatitis.
by Xu, Ping
2480 Pioglitazone has anti-inflammatory effects in patients with Type 2 diabetes.
by Heliövaara, M K